In the Pipeline/home/corante/public_html/pipeline/
en-usderekb.lowe@gmail.com2015-03-30T09:59:23-05:00hourly12000-01-01T12:00+00:00Transferring Compounds From Pharma to Academiahttp://pipeline.corante.com/archives/2015/03/30/transferring_compounds_from_pharma_to_academia.php
Here's a look from Bayer at their experiences providing vitamin D receptor ligands to the academic community over the last twenty years (which takes the compounds back into their Schering AG origins). Overall, they've found that the compounds seem to...77676@/home/corante/public_html/pipeline/Academia (vs. Industry)2015-03-30T09:59:23-05:00Advice for Academic Entrepreneurshttp://pipeline.corante.com/archives/2015/03/25/advice_for_academic_entrepreneurs.php
Since I've mentioned a recent book on academic drug discovery, I also wanted to highlight this article at Nature Biotechnology on university tech transfer offices (TTOs). The authors, mostly from a list of high-profile research universities (Oxford, Stanford, UCSF, University...77667@/home/corante/public_html/pipeline/Academia (vs. Industry)2015-03-25T06:49:44-05:00Drug Development for Academicshttp://pipeline.corante.com/archives/2015/03/19/drug_development_for_academics.php
I have a book review out in Nature Chemical Biology of A Practical Guide to Drug Development in Academia. As you'll see, I liked it, finding it a very useful guide to real-world drug discovery for people who are interested...77658@/home/corante/public_html/pipeline/Academia (vs. Industry)2015-03-19T08:18:26-05:00What Industry Would Like to Hear Abouthttp://pipeline.corante.com/archives/2015/03/17/what_industry_would_like_to_hear_about.php
Here's a good paper from Phil Baran and co-workers in Accounts of Chemical Research on the relationship between industrial and academic research. It's illustrated with examples from his own work, such as the ingenol synthesis, and with new synthetic methods...77653@/home/corante/public_html/pipeline/Academia (vs. Industry)2015-03-17T07:13:23-05:00Drug Industry Trials vs. NIH-Funded Ones: Who Reports on Time?http://pipeline.corante.com/archives/2015/03/12/drug_industry_trials_vs_nihfunded_ones_who_reports_on_time.php
This article at NEJM is looking at how well clinical trial results are made public, which has been a big topic over the last few years. Let me say up front that the results are quite interesting, and that some...77646@/home/corante/public_html/pipeline/Clinical Trials2015-03-12T06:36:14-05:00The State of US Medical Researchhttp://pipeline.corante.com/archives/2015/01/21/the_state_of_us_medical_research.php
Here's a look at the state of medical research in the US versus other developed countries (open-access article at JAMA). Some things to note from that chart: (1) research funding has been pretty flat the last few years, with the...77551@/home/corante/public_html/pipeline/Drug Industry History2015-01-21T07:41:54-05:00More Odd Compoundshttp://pipeline.corante.com/archives/2015/01/07/more_odd_compounds.php
When you look into the literature on small-molecule agents for really tricky targets, something stands out to medicinal chemists immediately: the structures start to get strange. Examples of this sort of thing are beyond counting, but this recent paper will...77528@/home/corante/public_html/pipeline/Academia (vs. Industry)2015-01-07T07:07:02-05:00Ambition From Recursionhttp://pipeline.corante.com/archives/2014/12/10/ambition_from_recursion.php
Here's one to put in the "hubris" file - we'll have to wait to see whether or not it's followed by the traditional divine retribution. According to Drug Discovery & Development (note: corrected source), startup Recursion Pharmaceuticals, out of the...77495@/home/corante/public_html/pipeline/Academia (vs. Industry)2014-12-10T07:04:34-05:00Postdoctoral Life (AKA What Shortage?)http://pipeline.corante.com/archives/2014/12/05/postdoctoral_life_aka_what_shortage.php
. . .is not very pleasant, according to this report. It never has been, but it's not getting any better. This should sound familiar to many people: it is notoriously difficult to determine how many postdoctoral scholars there are, let...77487@/home/corante/public_html/pipeline/Business and Markets2014-12-05T09:17:16-05:00Francis Collins Knows Why We Don't Have An Ebola Vaccinehttp://pipeline.corante.com/archives/2014/10/24/francis_collins_knows_why_we_dont_have_an_ebola_vaccine.php
NIH Director Francis Collins has been saying that if only the agency's budget hadn't been cut, that we would already have an Ebola vaccine. He tried this line out during recent Congressional testimony, and apparently liked it enough that he...77404@/home/corante/public_html/pipeline/Infectious Diseases2014-10-24T06:13:46-05:00Different Screening, Different Thermodynamics?http://pipeline.corante.com/archives/2014/10/17/different_screening_different_thermodynamics.php
Chris Lipinski and the folks at Collaborative Drug Discovery send word of an interesting webinar that will take place this coming Wednesday (October 22nd) at 2 PM EST. It's on enthalpic and entropic trends in ligand binding, and how various...77391@/home/corante/public_html/pipeline/Drug Assays2014-10-17T06:57:19-05:00PAINS Go Mainstreamhttp://pipeline.corante.com/archives/2014/09/26/pains_go_mainstream.php
Well, I'm back in the Eastern Time Zone after flying in from Basel (and Amsterdam) yesterday. And the first thing I wanted to mention was this article from Jonathan Baell and Michael Walters inNature, on the PAINS compounds. It's good...77350@/home/corante/public_html/pipeline/Drug Assays2014-09-26T06:57:21-05:00A Day of Irreproducibility In Cambridgehttp://pipeline.corante.com/archives/2014/09/19/a_day_of_irreproducibility_in_cambridge.php
I wanted to mention that there's an interesting symposium on "Irreproducibility in Target Validation" taking place at Novartis (Cambridge, MA) next month, October 23. This is a topic that many an industrial biopharma researcher can relate to, and as academic...77338@/home/corante/public_html/pipeline/The Scientific Literature2014-09-19T06:51:02-05:00Are Your Compounds Ugly? Do You Know?http://pipeline.corante.com/archives/2014/09/04/are_your_compounds_ugly_do_you_know.php
A reader sends along this paper, on some small molecules targeting the C2 domain of coagulation factor VIII. It illustrates some points that have come up around here over the years, that's for sure. The target is not a particularly...77313@/home/corante/public_html/pipeline/The Scientific Literature2014-09-04T06:14:26-05:00The Prospects of an Academic Jobhttp://pipeline.corante.com/archives/2014/07/15/the_prospects_of_an_academic_job.php
Over the years, there have been more comments than anyone can count here on the often-grim employment picture for chemistry and biology employment in biopharma. Plenty of people here (myself included) can speak from experience. But we should also remember...77242@/home/corante/public_html/pipeline/Academia (vs. Industry)2014-07-15T06:12:42-05:00